Who to call at Lyell Immunopharma, Inc., and when
Fundz watches for the moments Lyell Immunopharma, Inc. starts buying, and tells you who to reach.
- An alert the day Lyell Immunopharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lyell Immunopharma, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lyell Immunopharma, Inc.. With Fundz connected, it knows.
Lyell Immunopharma, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
lyell.com2 executive changes at Lyell Immunopharma in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
On October 31, 2025, Lyell Immunopharma's board appointed CEO Lynn Seely, M.D. as interim principal financial officer and named Veronica Sanchez Bulis as principal accounting officer. The filing changes who signs the company's financial reporting roles, and the company has not disclosed a reason beyond general corporate developments.
Key Takeaways
Dr. Lynn Seely, who already serves as President and CEO and as a director, now also acts as interim principal financial officer, concentrating executive and financial reporting roles in one person.
Veronica Sanchez Bulis was appointed principal accounting officer, filling a separate financial reporting role alongside the interim PFO designation.
2 more takeaways
Related Filings (1)
1 more filing from Lyell Immunopharma, Inc. in the last 90 days
Filing Overview
What This Means
Lyell Immunopharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.